Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710889 · ClinicalTrials.gov registry record · Phase 3
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
A Phase 3 study, sponsored by Radius Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT03710889 is a Phase 3 study that has completed, run by Radius Health. The registered enrollment target is 23 participants.
The verdict
NCT03710889, a Phase 3 study, has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.
Interventions
- DRUG Abaloparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-09-20 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03710889
The ClinicalTrials.gov registry entry for NCT03710889 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radius Health, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abaloparatide is the first listed.
NCT03710889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03710889 about?
NCT03710889 is a clinical study titled "Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption". The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.
What is the current status of trial NCT03710889?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2018-09-20. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03710889?
The interventions under investigation include: Abaloparatide (DRUG).
Who is sponsoring clinical trial NCT03710889?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.